Donepezil Tablets

Project Image
Thumb Image

Therapeutic Indication

Alzheimer’s disease (mild to moderate dementia)
Severe Alzheimer’s dementia (symptomatic treatment)
Cognitive decline associated with neurodegenerative disorders
+91 85919 78885

Donepezil

Tablet

Donepezil is a centrally acting reversible acetylcholinesterase inhibitor used to improve cognition and memory in patients with Alzheimer’s disease. It enhances cholinergic neurotransmission by preventing breakdown of acetylcholine in the brain.

Speciality Neurology | Psychiatry | Cognitive Disorders
Tags Alzheimer’s | Dementia | Cognitive Decline
Strength
  • 25 mg
  • 50 mg
  • 100 mg
Packing Size
  • 10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Donepezil selectively and reversibly inhibits acetylcholinesterase, the enzyme responsible for hydrolyzing acetylcholine. By increasing acetylcholine concentration in the synaptic cleft, it enhances cholinergic transmission in the cerebral cortex and hippocampus, improving cognition, memory, and daily functioning in Alzheimer’s patients.

Pharmacokinetics

  • Bioavailability: ~100%
  • Peak plasma concentration: 3–4 hours
  • Protein binding: ~95%
  • Metabolism: Hepatic via CYP2D6 and CYP3A4
  • Half-life: ~70 hours (allows once-daily dosing)
  • Excretion: Renal and biliary routes

Side Effects

  • Nausea
  • Diarrhea
  • Insomnia
  • Muscle cramps
  • Fatigue
  • Bradycardia (rare)

Contraindication

  • Hypersensitivity to Donepezil or piperidine derivatives
  • Severe hepatic impairment
  • Pregnancy and lactation (unless benefits outweigh risks)

Interaction

  • Anticholinergic drugs: Reduced efficacy
  • Cholinergic agonists: Additive effects
  • CYP3A4/CYP2D6 inhibitors (e.g., ketoconazole, quinidine): ↑ Donepezil levels
  • CYP inducers (e.g., phenytoin, carbamazepine): ↓ Donepezil levels

Warning and Precautions

  • Monitor cardiac function in patients with conduction abnormalities
  • Use caution in patients with asthma or COPD (cholinergic effects)
  • Risk of gastrointestinal bleeding in patients with ulcers
  • Adjust dose in hepatic impairment

Dosage

As directed by the Physician.

Disclaimer

All product details on this website are for reference and informational purposes only and are not directed at patients or consumers.
As a contract manufacturer, DM Pharma Pvt Ltd is not responsible for the marketing or end use of these products and disclaims all liability arising from reliance on this information.
Please consult a healthcare professional before using any medicinal product.